{"id":9256,"date":"2020-04-30T18:00:22","date_gmt":"2020-04-30T12:30:22","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9256"},"modified":"2023-02-10T12:07:28","modified_gmt":"2023-02-10T06:37:28","slug":"recent-pharma-happenings-for-gilead-biontech-pfizer-merck","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck","title":{"rendered":"Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a0832cd3530e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a0832cd3530e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck\/#Remdesivir_of_Gilead_accelerates_COVID-19_recovery\" >Remdesivir of Gilead accelerates COVID-19 recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck\/#Merck_pact_with_Almac_for_neurodegenerative_diseases\" >Merck pact with Almac for neurodegenerative diseases&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck\/#Pfizer_BioNTech_finish_dosing_in_COVID-19_vax_test\" >Pfizer, BioNTech finish dosing in COVID-19 vax test<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck\/#Taysha_Gene_Therapies_plans_to_run_for_clinical_trails\" >Taysha Gene Therapies plans to run for clinical trails&nbsp;&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-remdesivir-of-gilead-accelerates-covid-19-recovery\"><span class=\"ez-toc-section\" id=\"Remdesivir_of_Gilead_accelerates_COVID-19_recovery\"><\/span><strong>Remdesivir of Gilead accelerates COVID-19 recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gilead Sciences&#8217; Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-novel-coronavirus-19-therapeutic-pipeline-vaccines-diagnostics-competitive-landscape\">COVID-19<\/a> patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against placebo in more than thousands of patients.<\/p>\n\n\n\n<p>The Food and Drug Administration (FDA) could give the nod to remdesivir for emergency use according to the results.<\/p>\n\n\n\n<p>The study had carried out at 68 sites around the world, recovery as being healthy to return normal activity level. The trial was not reserved for the sickest of patients, not like other trials that only comprised of patients with severe disease, but the patients still had to be hospitalized with confirmed <a href=\"https:\/\/www.delveinsight.com\/report-store\/covid-19-coronavirus-pipeline-insights\">COVID-19<\/a> infection along with confirmation of lung involvement involving the need for supplemental oxygen or mechanical ventilation. The study did not cover the patients with milder, cold-like symptoms or those who were asymptomatic.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-merck-pact-with-almac-for-neurodegenerative-diseases\"><span class=\"ez-toc-section\" id=\"Merck_pact_with_Almac_for_neurodegenerative_diseases\"><\/span><strong>Merck pact with Almac for neurodegenerative diseases&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Merck has the latest deal which is an R&amp;D pact with Almac Discovery. The deal is centred on deubiquitinases, which is a family of enzymes that play many roles in cellular regulatory processes.<\/p>\n\n\n\n<p>The duo will recognize and create small molecule inhibitors of deubiquitinases, or DUBs, for the treatment of the neurodegenerative diseases. Merck will pick up lead optimization, preclinical and clinical development and commercialization. They did not reveal the financial terms or specific disease areas of interest.<\/p>\n\n\n\n<p>There are some clear, neural pathological processors that both partners are very engrossed in and contemplate an essential role for certain [DUB-targeting] molecules. They will explore those pathological processes. At their core, DUBs eliminate ubiquitin from proteins and other molecules. Ubiquitin is a protein, cells utilize to tag damaged, or unneeded proteins for degradation in a protein complex called a proteasome.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pfizer-biontech-finish-dosing-in-covid-19-vax-test\"><span class=\"ez-toc-section\" id=\"Pfizer_BioNTech_finish_dosing_in_COVID-19_vax_test\"><\/span><strong>Pfizer, BioNTech finish dosing in COVID-19 vax test<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Pfizer and partner BioNTech are keeping pace with the speed of the pandemic as they complete dosing in the first cohort of their <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\">COVID-19<\/a> inoculation test.&nbsp;&nbsp;<\/p>\n\n\n\n<p>The biotech-pharma partners informed that the first cohort of BioNTech&#8217;s phase 1\/2 clinical trial has been dosed in BioNTech&#8217;s native Germany and comes after a week when they were given the clear run trials in the country. It is a small study with just 12 participants, but all have been dosed with BioNTech&#8217;s vaccine candidate BNT162 six days after the trial commenced.<\/p>\n\n\n\n<p>The full dose-escalation portion of the Phase 1\/2 trial will run around 200 healthy subjects between the ages from 18 to 55 and will aim a dose range of 1 \u00b5g to 100 \u00b5g that targets to determine the optimal dose for further studies as well as to access the safety and immunogenicity of the vaccine. The study will also evaluate the effects of repeated vaccination following a prime injection for the three vaccine candidates that comprise of uridine-containing mRNA or nucleoside-modified mRNA.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-taysha-gene-therapies-plans-to-run-for-clinical-trails\"><span class=\"ez-toc-section\" id=\"Taysha_Gene_Therapies_plans_to_run_for_clinical_trails\"><\/span><strong>Taysha Gene Therapies plans to run for clinical trails<\/strong>&nbsp;&nbsp;<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The team that developed Zolgensma is now for round two. A group of former AveXis executives and investors revealed a new gene therapy company. With 15 programs, USD 30 million in seed funding and an unparalleled collaboration with UT Southwestern Medical Center, Taysha Gene Therapies slates to be in the clinic year-end.<\/p>\n\n\n\n<p>It is working on adeno-associated vector (AAV) gene therapies for monogenic diseases\u2014diseases that are caused by a defect in a single gene of the central nervous system. Taysha&#8217;s lead program aims GM2 gangliosidosis, a very rare disorder that progressively destroys nerve cells in the brain and spinal cord; however, the company&#8217;s portfolio comprises of more prevalent conditions.<br>The company schedules to commence clinical trials for three more programs by the end of the 2021 year- treatments for <a href=\"https:\/\/www.delveinsight.com\/report-store\/rett-syndrome-market\">Rett syndrome<\/a>, a neurodevelopmental disorder; SURF1 deficiency, the most frequent cause of Leigh syndrome; and SLC6A1 genetic epilepsy that is similar to <a href=\"https:\/\/www.delveinsight.com\/report-store\/dravet-syndrome-market\">Dravet syndrome<\/a>.<br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Remdesivir of Gilead accelerates COVID-19 recovery Gilead Sciences&#8217; Remdesivir shows the first data from a placebo-controlled study. Remdesivir decreases recovery time for hospitalized COVID-19 patients by four days or 31% as published in a National Institutes of Health-sponsored study setting the drug against placebo in more than thousands of patients. The Food and Drug Administration [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9970,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1287,16668,794,349,395,420,460,639,16756,18283,18282],"industry":[17225],"therapeutic_areas":[17229,17245],"class_list":["post-9256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biontech","tag-dravet-syndrome","tag-gilead","tag-latest-pharma-news","tag-merck","tag-news","tag-pfizer","tag-pharma-news","tag-remdesivir","tag-rett-syndrome","tag-taysha-gene-therapies","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Gilead, Merck, Almac, Taysha Gene Therapies<\/title>\n<meta name=\"description\" content=\"Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Gilead, Merck, Almac, Taysha Gene Therapies\" \/>\n<meta property=\"og:description\" content=\"Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-30T12:30:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T06:37:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/25113758\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Gilead, Merck, Almac, Taysha Gene Therapies","description":"Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Gilead, Merck, Almac, Taysha Gene Therapies","og_description":"Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-04-30T12:30:22+00:00","article_modified_time":"2023-02-10T06:37:28+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/25113758\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck","name":"Pharma News | Gilead, Merck, Almac, Taysha Gene Therapies","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/25113758\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck.jpg","datePublished":"2020-04-30T12:30:22+00:00","dateModified":"2023-02-10T06:37:28+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Remdesivir accelerates for COVID-19 recovery; Merck pact with Almac; Pfizer, BioNTech finish dosing in; Taysha Gene Therapies for trials","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/25113758\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/25113758\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck.jpg","width":772,"height":482,"caption":"pharma-news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/25113758\/recent-pharma-happenings-for-gilead-biontech-pfizer-merck-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioNTech<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Dravet syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">remdesivir<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rett Syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Taysha Gene Therapies<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">BioNTech<\/span>","<span class=\"advgb-post-tax-term\">Dravet syndrome<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">remdesivir<\/span>","<span class=\"advgb-post-tax-term\">Rett Syndrome<\/span>","<span class=\"advgb-post-tax-term\">Taysha Gene Therapies<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Apr 30, 2020","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Apr 30, 2020 6:00 pm","modified":"Updated on Feb 10, 2023 12:07 pm"},"featured_img_caption":"pharma-news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9256"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9256\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9970"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9256"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9256"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}